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Abstract 
Purpose: Permanent breast seed implant (PBSI) using 103Pd is emerging as an effective adjuvant radiation 
technique for early-stage breast cancer.  However, clinical dose evaluations follow the water-based TG-43 
approach with its considerable approximations.  Towards clinical adoption of advanced TG-186 model-
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based dose evaluations, this study presents a comprehensive investigation for PBSI considering both 
target and normal tissue doses. 
 
Methods and Materials:  Dose calculations are performed with the free open-source Monte Carlo (MC)  
code, egs_brachy, using 2 types of virtual patient models: TG43sim (simulated TG-43 conditions: all 
water with no interseed attenuation) and MCref (heterogeneous tissue modelling from patient CT, 
interseed attenuation, seeds at implant angle) for 35 patients.  Sensitivity of dose metrics to seed 
orientation and the threshold for glandular/adipose tissue segmentation are assessed. 
 
Results: In the target volume, D90 is 14.1±5.8% lower with MCref than with TG43sim, on average.  
Conversely, normal tissue doses are generally higher with MCref than with TG43sim, e.g., by 22±13% 
for skin D1cm2, 82±7% for ribs Dmax, and 71±23% for heart D1cm3.   Discrepancies between MCref and 
TG43sim doses vary over the patient cohort, as well as with the tissue and metric considered.  Doses are 
sensitive to the glandular/adipose tissue segmentation threshold with differences of a few percent in target 
D90. Skin doses are particularly sensitive to seed orientation, with average difference of 4% (maximum 
28%) in D1cm2 for seeds modelled vertically (egs_brachy default) compared with those aligned with 
implant angle. 
 
Conclusions: TG-43 dose evaluations generally underestimate doses to critical normal organs/tissues 
while overestimating target doses.  There is considerable variation in MCref and TG43sim on a patient-
by-patient basis, suggesting that clinical adoption of patient-specific MC dose calculations is motivated. 
The MCref framework presented herein provides a consistent modelling approach for clinical 
implementation of advanced TG-186 dose calculations.  
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Introduction 
Permanent breast seed implant (PBSI) brachytherapy using low-dose-rate (LDR) 103Pd seeds is an 
attractive, single-day technique for adjuvant radiation in early-stage breast cancer (1). PBSI has been 
shown to be an effective treatment option with high rates of patient satisfaction and very good cosmesis 
(2;3).   
 
Clinical dosimetric results are determined using the formalism of Task Group (TG) 43 of the American 
Association of Physicists in Medicine (AAPM) (4). This formalism neglects important dosimetric effects 
of tissue composition and inhomogeneities, influences of the brachytherapy applicators or seeds, as well 
as the finite extent of the patient. Breast brachytherapy in general has been identified as a treatment site 
where neglecting these factors can have a significant impact on dose calculation accuracy, with LDR 
breast brachytherapy being particularly sensitive to tissue composition and interseed attenuation (5). 
Preliminary studies indicate that TG-43 calculations can overestimate doses to the PTV by as much as 
35% while skin doses are underestimated (6;7;8;9). To achieve accurate dosimetry, advanced model-
based dose calculation algorithms (MBDCAs) are being developed, and their clinical adoption is 
recommended by the joint TG-186 of the AAPM–European Society for Therapeutic Radiotherapy and 
Oncology (ESTRO)–Australasian Brachytherapy Group (10).  
 
 Early studies applying Monte Carlo (MC) to PBSI dose calculations have investigated issues related to 
the development of the virtual patient models needed for MC simulations, including evaluation of 
different algorithms to mitigate artifacts in post-implant CT images (7) and subsequent assignment of 
tissue elemental compositions to voxels (6;7;11). In addition, interseed attenuation has been considered, 
and patient specific MC doses have been compared to those from TG-43 calculations (6;7;8).  These 
works suggest patient-specific MC models are required for accurate dose evaluation, and highlight the 
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importance of the adoption of a well-defined and consistent MC approach as clinics move towards 
advanced MBDCAs, but further research is needed. 
 
With the aim of facilitating clinical adoption of advanced MBDCAs for PBSI, herein we present a 
dosimetric evaluation for a new patient cohort using a recently-developed and released, open-source MC 
code, egs_brachy (12). Dose metrics are presented for the target, skin, as well as other normal tissues - to 
our knowledge, the first comprehensive presentation of patient-specific PBSI MC doses in the scientific 
literature. As MC dose calculations are inherently sensitive to patient modelling assumptions (7), we 
present a MC approach that follows TG-186 recommendations (10) and builds on the published literature 
(6;7;11). Results are compared to calculations using TG-43 assumptions. Additionally, we assess 
sensitivity to the threshold for segmenting adipose and glandular tissues in the breast, and seed 
orientation. 
 
Methods and Materials 
Clinical data 
Anonymized post-implant CT images (Day 0; GE Lightspeed helical scan at 120 kV, 250 mA; resolution: 
2 mm axial and 0.977 to 1.25 mm in-plane) from 35 PBSI patients treated consecutively at BC Cancer-
Kelowna between July 2012 and February 2016 are retrospectively analyzed in this REB approved study. 
Patient characteristics are described elsewhere (3).  Each patient had an evaluative target volume (ETV, 
seroma plus 5mm) contoured (13). Additionally, normal breast, ribs, skin (2 mm, internal from body), 
ipsilateral lung, heart, and chest wall were contoured to evaluate dose to organs at risk (OAR). Central 
coordinates of 52 to 118 TheraSeed 200 (Theragenics, Buford, USA) 103Pd seeds and their air kerma 
strengths (range 2.3-2.8 U) were recorded along with the angle of implant (range 10º-70º) (3). For all 
patients, the prescription dose was 90 Gy (D100). 
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Virtual patient and source models 
Virtual patient models must be developed for MC dose evaluations. These models are based on CT 
images: the CT calibration curve is used to convert Hounsfield units to mass density for each voxel 
(Supplementary Material Table 1, Figure 1) and a tissue assignment scheme is then used to assign mass 
elemental compositions (10;14) to different tissues (Supplementary Material Table 1) according to voxel 
mass density, with reference to the relevant contour (Fig 1a).  
 
Here we develop virtual patient models from post-implant CT images where the presence of implanted 
brachytherapy sources results in attenuation artifacts (7;15) that, if not accounted for, can lead to errors 
when applying the tissue assignment scheme and thus corresponding large dose errors. To ameliorate this, 
we apply a simple threshold replacement algorithm for metallic artifact reduction (7); note that the CT 
scanner does not have on-board metallic artifact reduction. In simple threshold replacement, the mass 
densities for relevant voxels near seeds are compared to a threshold value and if the threshold is exceeded 
their mass density is replaced with a representative density. Here, mass densities for all voxels within a 
cylinder (radius = 0.5cm, extending ±2 slices) centered on the seed are compared to threshold of 1.16 
g/cm3 (corresponding to the threshold for assignment of calcification, Fig 1a). Voxels that exceed this 
value have their mass density replaced with the mean patient ETV density, 0.917 g/cm3. Similarly, this 
mass density replacement is applied to any dark streak artifacts inside the breast using a threshold of 
0.800 g/cm3, well below the density of normal breast tissues. 
 
Following metallic artifact reduction, two full-tissue tissue assignment schemes are applied, differing only 
in the mass density boundary used for segmentation of adipose and glandular tissues, ρA/G. For the 
reference MC approach, MCref, ρA/G is determined for each patient by fitting a histogram of breast voxel 
mass densities to two Gaussian distributions representing adipose and glandular tissues and selecting the 
halfway point between the densities corresponding to the distribution peaks.  Resulting patient-specific 
ρA/G range from 0.9179 to 0.9700 g cm−3, with a mean value of 0.9476 g cm-3. To assess calculation 
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sensitivity to ρA/G, the patient cohort mean ρA/G of 0.9476 g cm-3 is applied to all data sets in the second 
tissue assignment scheme to generate virtual patient models with a fixed tissue boundary, MCfixed. As 
well as the full-tissue models, a homogeneous water (uniform mass density 0.998 g/cm3) virtual patient 
model with identical voxel boundaries is developed for TG43sim simulations.  
 
Additionally, we model three seed orientations to investigate the sensitivity to seed angle (Fig 1c).  The 
most realistic model, with seeds oriented along the patient-specific angle of implant, is used as the 
standard.  This is compared to seeds modelled at an angle of 45º within the transverse plane (adjusted 
according to left/right side, MCref-45) and seeds along the z-axis (MCref-z superior-inferior).  MCref-
45 serves to approximate the implant angle based on the geometry of the implant procedure, relevant in 
case implant angle is unknown for other centers/researchers.  MCref-z represents the default alignment 
(seed axis aligned vertically, z-direction) in egs_brachy. 
 
MC simulations 
MC simulations are carried out with the EGSnrc (16) (v2016) application egs_brachy (version 
2016.09.01) (12;17). Detailed, previously-benchmarked (12) geometric models of TheraSeed 200 sources 
are superimposed on the virtual patient model described above to carry out the following MC simulations: 
• MCref (reference scenario): full-tissue patient model with patient-specific ρA/G (mass-density 
threshold for adipose/glandular tissue segmentation); seeds at implant angle, interseed attenuation 
included 
• TG43sim (simulation of TG-43 conditions): all-water patient model; seeds at implant angle with 
no interseed attenuation 
• MCfixed (assess sensitivity to ρA/G): full-tissue patient model with cohort-average (“fixed”) ρA/G 
= 0.9476 g/cm3; seeds at implant angle, interseed attenuation included 
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• MCref-45 (assess sensitivity to seed in-plane orientation): full-tissue patient model with patient 
specific ρA/G; seeds at 45°, interseed attenuation included 
• MCref-z (assess sensitivity to seed orientation): full-tissue patient model with patient-specific 
ρA/G; seeds along z-axis, interseed attenuation included 
Initial photon energies are generated using the 103Pd spectrum from TG-43 (4). Photon transport is 
modelled to 1 keV, scoring collision kerma to the local voxel medium (using mass-energy absorption 
coefficients pre-calculated with EGSnrc application g) to approximate dose (Dm,m, dose-to-medium (10)). 
MC simulation parameters are consistent with earlier work benchmarking egs_brachy (12;17) 
(Supplementary Material Table 3).  
 
Simulations involve 109 histories, resulting in sub-1% statistical uncertainties on voxel doses in the ETV 
and the skin (primary OAR); heart D1cm3 voxels have sub-1.5% uncertainties (for the 27/35 patients with 
heart D1cm3 greater than 1 Gy).  Each simulation requires 8 to 12 computational hours (on a decade-old 
computer cluster comprised of CPUs of varying speeds); however, uncertainties of order 2% which are 
sufficient for clinical applications would require less than a minute per patient using a multicore processor 
(2 GB of RAM needed). 
 
Dose and volume metrics are extracted from dose volume histograms for the target and organs at risk.  
Dose metrics include D90 (minimum dose in the hottest 90% of the ETV), Dmax (highest dose received by 
a single voxel within the contours for the skin, ribs, chest, heart), D1cm2 (highest dose received by a 
contiguous 1 cm2 area in the skin), and D1cm3 (highest dose received by a contiguous 1 cm3 volume in the 
breast or heart).  Volume metrics, Vx, represent the fraction of a specified region receiving x percentage of 
the prescribed dose, and include V100, V150, V200 in the ETV, V150 for the breast, and V5 for the skin. 
 
Dose metrics from MCref are compared with those extracted from the 4 alternate models (Alt) by means 
of the percent difference computed for each patient for that metric, M, as follows: 








Patient-specific MCref dose distributions demonstrate considerable discrepancies in comparison with 
TG43sim doses (Fig. 2a-c).  Discrepancies may be observed throughout patient tissues/volumes, and 
there are abrupt discontinuities in doses at the interfaces of different tissues (due to their different 
radiological properties, mass-energy absorption coefficients, arising from different elemental 
compositions). For the ETV, MCref doses are lower than TG43sim by up to 40%, with a few exceptions  
where doses to glandular tissue are higher (e.g., subset of voxels in ETVs shown in Fig.2a,c in yellow-
orange) due to the interplay of mass-energy absorption coefficients and fluence differences compared 
with homogeneous water (TG43sim). In contrast, doses to the skin are higher for MCref by up to a factor 
of 2 in comparison to TG43sim. Similarly, TG43sim typically underestimates doses to other normal 
tissues e.g., ribs, chest wall. 
 
Target (ETV) dose metrics 
Voxel doses are generally overestimated over the whole ETV for TG43sim compared with MCref, 
reflected in the shapes of dose-volume histograms (DVHs; Fig. 2d-f).  Differential DVHs differ for 
MCref and TG43sim for the same patient as well as between different patients (Fig. 2(e-g)), with the 
MCref curves typically peaked at a lower dose compared to TG43sim for each patient.  Across the 
cohort, ETV dose metrics are consistently overestimated with TG43sim compared with MCref. Figure 3a 
shows D90 on a patient-by-patient basis over the whole cohort with TG43sim consistently higher than 
MCref by 14%, and mean D90 is 91.7 ± 19.0 Gy (MCref) compared with 105.1 ± 24.4 Gy (TG43sim) 
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(Table 1).  Correspondingly, target coverage is overestimated by TG43sim, as evidenced by volume 
metrics in Table 1 (for the whole cohort as well as example patients) and Fig. 4. 
 
Normal tissues 
There is considerable variation in the skin doses between patients, e.g., with D1cm2 varying from a few Gy 
(min 6.6 Gy (MCref), 2.2 Gy (TG43sim) for patient #2) to > 100 Gy (max 177 Gy (MCref), 160 Gy 
(TG43sim) for patient #30) – Fig. 3b. However, TG43 underestimates D1cm2 skin doses in comparison 
with MCref consistently across the cohort by average 22% ± 13% (Table 1). Maximum skin dose, the 
highest dose received by a single skin voxel in a patient, is generally underestimated by TG43sim, but 
with some exceptions (figure 4).  Dmax for skin varies dramatically between patients ranging from 7.5 Gy 
(patient #2) to 892 Gy (patient #8) for MCref. 
 
In general, TG43sim underestimates doses to normal tissues (ribs, chest wall, heart, lung, breast) – table 1 
and figure 4. Large discrepancies are observed for rib and chest wall, for which single voxel maximum 
doses across the cohort increase by an average of 82.3% (ribs) and 29.6% (chest wall) for MCref 
compared to TG43sim. Likewise, the mean V100 increases by 84% in the ribs and 43% for chest wall. 
 
Heart doses are generally low, with no heart tissue voxel in any patient receiving more than 50% (45 Gy) 
of the prescription dose and very few patients (6/35) with non-zero values for heart V10. Likewise, mean 
heart dose evaluated with TG43sim is low (0.01 to 0.45 Gy) and the mean heart dose increases by 12 to 
93% with MCref. Patients with implants in their left breast consistently receive a higher mean heart dose 
(evaluated with TG43sim or MCref). 
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Doses to the lung are also very small. Extracted V5 and V20 metrics see significant increases (45% and 
5.9% on average, respectively) in the transition from TG43sim to MCref patient models.  The 
corresponding absolute mean MCref V5 and V20 values are very low, at only 7% and 0.8% respectively. 
 
V150 for the entire treated breast is overestimated with TG43sim by up to 53% compared with MCref 
(trend similar to those observed for target metrics). 
 
Sensitivity to virtual patient and source modelling 
Over the patient cohort, changing the mass density used for the adipose/glandular tissue segmentation 
boundary (ρA/G) from a value specific to each patient (MCref) to the cohort-mean ρA/G = 0.9476 g/cm3 
used for MCfixed, the mean absolute difference in ETV D90 values is 1.5%, with few patients having 
differences > 3% (figure 5). The general trend in target D90 variation between MCref and MCfixed may 
be related to the change in the relative fraction of tissue assigned to adipose or glandular tissues between 
the different models: D90 decreases with more adipose and increases with more glandular tissue (results  
not shown). The trends are similar for skin, however, the magnitude of differences in skin metrics 
between MCref and MCfixed are generally smaller. 
 
Seeds are modelled at the fiducial angle (of insertion) in the transverse plane for MCref, and differences 
are larger for seeds aligned axially (z) direction (MCref-z) compared with 45° within the transverse plane 
(MCref-45) – Fig. 5. Differences in ETV D90 for MCref-z relative to MCref are greater than 2% in over 
half the cohort, with a maximum %Δ of 8%. Seed orientation can have a considerable effect on skin peak 
dose and D1cm2 as high skin dose areas may be due to only one or a few seeds in close proximity to the 
skin, with different seed orientations resulting in even greater proximity. Photons are not emitted 
isotropically from the Theragenics model 200 seeds (which are not spherically symmetric), and different 
seed orientations can result in appreciable differences in skin dose metrics. Skin dose metrics for seeds at 
the 45° angle (MCref-45) are in closer agreement with MCref than MCref-z. The average difference 
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between skin D1cm2 values between MCref and MCref-z is 4%, with one patient differing by 28%.  Rib 
and chest wall tissues are also often located close enough to seed positions for changes in seed orientation 
to impact dose.  In rib and chest wall tissues, the presence of cortical bone (with its high mass-energy 
absorption coefficient and density) means that even relatively small changes in photon fluence and spectra 
can result in considerable dose differences, especially comparing peak dose (in a single voxel) Comparing 
MCref-z and MCref, chest wall and rib peak doses differ by up to 47%; MCref and MCref-45 peak 
doses differ by up to 24%. 
 
Discussion 
It has long been recognized that TG-43 based dose calculations have limited the accuracy of 
brachytherapy dose determinations. Current efforts to develop MBDCAs for brachytherapy seek to 
provide a practical, consistent and accurate means of calculating and evaluating dose. As we move 
towards this goal, it is necessary to compare current techniques to the new in order to understand how 
prescriptions and OAR dose-limits will need to change to better reflect what is actually being delivered. 
 
This retrospective MC study demonstrates large differences in dose distributions between the clinical, 
water-based TG-43 approach (TG43sim) and our reference patient-specific model-based TG-186 MC 
(MCref) dose calculations for all patients. TG43sim consistently overestimates dose in the tumour 
region, with differences in target D90 values routinely exceeding 10 Gy (figure 3, table 1). In healthy 
tissues, TG43sim underestimates dose, with skin doses often misrepresented by 20% or more; heart and 
lung metrics are tens of percent lower in TG43sim; TG43sim rib peak doses differ from MCref models 
by greater than a factor of three.  These differences between TG43sim and MCref dose metrics also have 
a large inter-patient variability, preventing the possible use of these percentage differences as correction 
factors for existing TG43sim methods. This motivates the clinical adoption of MBDCAs with 
corresponding patient-specific models, such as the MC calculations carried out herein, to accurately 
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account for the effects of non-water tissues and interseed attenuation in realistic patient anatomies and 
treatment geometries.  
  
A few other studies have investigated MBDCAs for PBSI (7;8;18), but modelling (virtual patient models, 
seed orientation), organ definition (target as seroma plus practice-specific margin; skin thickness), and 
dose evaluation (dose calculation algorithm) approaches are different, which means that doses calculated 
will inherently be different (10). Although this weakens the ability to make direct comparisons between 
PBSI dose distributions determined in various studies, overall trends for the target and organs at risk may 
be considered. However, as this is the first PBSI work to present metrics for normal tissues other than 
skin, it is not possible to compare these results directly to other cohorts. 
 
Within the target, all investigators found that TG43 overestimates D90, in agreement with the current 
study. Miksys et al (7) reported for 4 patients treated at The Ottawa Hospital Cancer Centre (TOHCC; 
same size ETV) that a TG43sim model overestimates D90 by 14.6% on average relative to patient-specific 
MC models, in concurrence with the 14.1% difference observed herein (table 1). Afsharpour et al (8) 
considered 28 patients treated at Sunnybrook Hospital, reporting results for the target defined as the 
seroma plus an additional 1 cm margin (ETV herein is seroma + 5 mm), observing a TG43 overestimation 
of 19.7% relative to MC calculations of D90. This larger decrease (compared to that observed herein or by 
Miksys et al (7)) is due to the larger volume of breast considered for the target and, typically, larger 
amount of adipose tissue included for which mass-energy absorption coefficients are considerably lower 
than for glandular tissue or water (7). 
 
Even when using simpler correction methods, TG43 is found to overestimate target doses. For a 140 
patient cohort treated at Sunnybrook, Mashouf et al examined using the inhomogeneity correction factor 
(ICF) method to account for inhomogeneities in TG-43 dose calculations for PBSI (18). They reported 
that the ICF-correction resulted in a 6% reduction in D90 values for the larger target (seroma + 1 cm) 
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relative to uncorrected TG43 (18). While the changes in dose created by the use of an ICF factor agree 
with the general dosimetric trends observed in patient-specific MC simulation, differences between ICF 
and TG43 doses are smaller than the differences between MC and TG43 doses, suggesting that the 
approximate ICF calculations may be underestimating the effects of non-water tissues, patient extent, and 
seeds.  
 
Skin is the normal tissue most likely to develop complications from PBSI treatments, and as such accurate 
skin dosimetry is of particular importance. Maximum and D1cm2 skin doses vary considerably on a patient-
to-patient basis due to patient anatomy (e.g., breast size) and implant location (target-skin proximity), but 
D1cm2 is considered a more reliable assessment of patient skin dose because maximum skin dose can be 
affected by one anomalously high dose voxel (13). Across our whole cohort, D1cm2 is consistently higher 
for MCref than for TG43sim (mean 22%), in overall accord with the 18% discrepancy observed for 
TOHCC patients (7) and trends for the Sunnybrook cohort (6).  
  
MBDCAs are inherently sensitive to patient and treatment-specific modelling assumptions (7;10). 
Previous work demonstrated sensitivity to tissue elemental composition and complexity in tissue 
assignment, focusing on target and skin metrics (7). In complement, the current study contributes to 
advancing the understanding of sensitivity of doses to adipose/glandular tissue segmentation threshold 
(ρA/G) and seed orientation. The current work is the first (to our knowledge) to assess sensitivity of doses 
to the adipose/glandular tissue segmentation threshold (ρA/G), with sub-1% discrepancies observed 
between individualized (MCref) and fixed (MCfixed) thresholds for most patients, however there are 
some outliers with differences in D90 near 5% (figure 5). As the density and proportion of breast adipose 
and glandular tissues varies considerably from patient-to-patient, it may be preferable for MBDCAs to 
use patient-specific ρA/G for derivation of virtual patient models where possible.  CT images were used 
herein for delineation and identification of tissues, including the segmentation of glandular and adipose 
tisuses.  Factors such as the machine’s settings (kVp) and image-processing algorithms, image resolution, 
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breast density, may affect the images and hence the development virtual patient models.  Future work 
may investigate the sensitivity of dose calculations to these parameters.  
 
The current study is also the first, to our knowledge, to consider realistic seed orientations and assess 
sensitivity of dose-volume metrics to seed orientation. Differences in D90 of greater than 2% are seen in a 
large portion of the cohort when comparing realistic (MCref) and axially-modelled (MCref-z) seed 
orientations, with even larger differences observed for skin, rib, and chest wall metrics (figure 5b). 
Differences are less substantial when seeds are modelled at 45° in the transverse plane (compared with 
MCref). These results motivate modelling seeds at the fiducial implant angle, to most closely 
approximate seeds’ orientation during treatment. 
 
Our current results may be used for quantitative evaluation of the PBSI treatments. Considering TG43sim 
doses, ETV D90 > 90 Gy was achieved in 25 of 35 cases (71%), compared to only 20/35 (57%) for MCref 
doses, with 3 cases having MCref D90 of 60 Gy (patients #7, 27, and 29). This highlights that full clinical 
adoption of MBDCA dose evaluations may necessitate prescription revision.  
 
For the skin, 43% of patients received D1cm2 > 90 Gy with some over 200 Gy using MCref, but these 
values are 22% lower on average using TG43, indicating that current dose limits will also need to be 
revised going forward with MBDCAs. Rib doses are also underestimated by TG43, with the volume 
receiving > 90 Gy increasing by a factor of 6 with MCref. However, adult cortical bone is not considered 
to be a relatively radiosensitive organ, and previous studies investigating brachytherapy treatments with 
125I sources implanted less than 0.5 cm from the ribs showed no osseous toxicity in a long-term 
retrospective analysis (19). Heart and lung doses are very low in both TG43 and MCref models.  
 
Mean heart V50 and V10 values are zero, and mean heart MCref doses below 0.60 Gy for all patients, 
while MCref patient lung V5 and V20 values are all < 10%. However, when heart D1cm3 metrics 
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determined using MCref are extracted, some patients have values above 10 Gy.  Although this is still well 
below the guidelines set to prevent pericarditis by the ‘Quantitative Analyses of Normal Tissue Effects in 
the Clinic’ (QUANTEC) study (20), it may be of clinical interest because the rate of long-term, post-
radiation major coronary events has been linked to heart dose with no apparent lower threshold (21). To 
prevent radiation induced pneumonitis, QUANTEC sets a limit of mean lung dose at 7 Gy, a much higher 
value than that received by all BC Cancer PBSI patients (as indicated by the low values of MCref patient 
lung V5 and V20 values).   
 
While PBSI treatments aim to minimize doses delivered to skin and other healthy tissues, there is 
currently little in the way of complication dose thresholds within the PBSI literature. The only 
demonstrated association is for skin dose (22), thus, to help position PBSI as a standard of care for early 
stage breast cancer, a move towards establishing quantitative, accurate, and repeatable dose thresholds is 
needed.  For accurate dose calculations to be widely adopted, a multi-institution retrospective study will 
be carried out that translates the TG-186 model-based dose calculation (MC simulation) methodology 
used in the current study to different clinical centers.  This will enable comparisons of MC and TG43 
doses across different cancer centers (with varying practices/methodologies in relation to seed strength, 
loading pattern, delivery/implant technique, and so on), and future prospective studies, e.g. to assess 
possible revision of prescription doses, choice of metrics with TG-186 treatment planning, and more. 
Treatment outcomes will then be considered in conjunction with accurate dose evaluation. Clinical 
experience indicates that the current delivered dose to the ETV is extremely effective. Thus, a change in 
calculation methodology to include patient specific mass-density corrections for adipose/glandular tissue 
segmentation and corrections for seed angle may show that we are delivering significantly less, but there 
is no need to increase our prescription to achieve what we thought was required. With regards to normal 
tissue calculations, we should be cognizant of the fact that we are actually delivering higher doses than we 
appreciated, especially to skin.  This will allow clarification of dose thresholds for toxicity and refine our 
efforts to minimize complications. 
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Conclusions 
The present work demonstrates that traditional TG43-based dose evaluation results in systematic 
inaccuracies in PBSI doses for both target and normal tissues, compared with patient-specific MC, across 
the cohort considered. Overall, the TG43 approach overestimates doses to the target, and consistently 
underestimates normal tissue doses (skin, ribs, chest wall, breast, heart, and lung). These discrepancies are 
considerable, with greater than 10% discrepancies observed for the target dose metrics (D90), and greater 
than 20% D1cm2 for skin and even larger for other normal tissues. This research motivates further work 
with other cohorts comparing full-tissue patient MC simulations with TG43 calculations for PBSI, 
towards clinical adoption of TG186 MBDCA, and outcomes studies to connect MC doses and treatment 
outcomes. Furthermore, this work provides impetus for widespread clinical adoption of advanced 
MBDCA to avoid systematic errors incurred with the TG43 approach. The presented MCref framework 
implemented with the freely-available open source egs_brachy code, may be useful for clinical adoption 
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Figures 
 
Figure 1: Development of simulation geometries: tissue assignment schemes for virtual patient models 
(MCref, MCfixed, TG43sim) with density boundaries indicated (left) and seed orientations (right) 
showing an example patient-specific implant angle (55o here) used for MCref, MCfixed, TG43sim; 
MCref-45 (45°in transverse plane); MCref-z (along z-axis, superior-inferior).  
  









   
 
   
 
Figure 2: Examples of 3 patients (#6, 14, 30) of (a-c) voxel-by-voxel ratios of MCref /TG43 in 1 
transverse layer (ETV contour in white); (d-f) dose-volume histogram (DVH); and (g-i) differential DVH 
in the ETV.  
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Figure 3: Values of (a) ETV (target) D90 and (b) skin D1cm2 versus patient number for TG43 (blue 
squares) and MCref  (red circles); horizontal lines indicate mean cohort values (and 90 Gy prescription 
dose – panel a).  
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Figure 4: Dose metric ratios for TG43sim relative to MCref for the target (ETV) and normal tissues 
(skin, ribs, chest, breast, heart and lung) represented by box and whiskers: each box extends from the 
lower to upper quartile values of the data, with a line at the median, whiskers show the full range of data, 
and “x” indicates the mean. 
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Figure 5: Sensitivity to MC modelling: dose metric ratios for alternative MC models (MCfixed, MCref-
45, MCref-z) relative to MCref for the target (ETV) and some normal tissues (skin, ribs, chest); box and 
whiskers are defined in figure 4 caption (symbols indicate means).  
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Tables 
Table 1  Summary of metrics for the cohort and 3 example patients for the evaluative target volume 





Ribs Chest Breast Heart Lung
D90 V100 V150 V200 D1cm2 Dmax Dmax Dmax V150 D1cm3 V5
Gy (frac) (frac) (frac) (Gy) (Gy) (Gy) (Gy) (cm
3
) (Gy) (frac)
MCref 91.7 0.894 0.637 0.341 84.4 187.9 746.3 927 33.0 4.38 0.0724
TG43sim 105.1 0.928 0.748 0.474 69.9 189.2 168.8 693 44.5 2.05 0.0396
%Δavg -14.1 -4.02 -18.3 -40.1 22.2 13.54 82.3 29.6 36.0 70.6 44.8
%Δstd 5.83 2.53 5.96 11.3 12.7 20.03 6.74 41.2 7.7 23.4 21.0
IQR(MCref) 26.4 0.0957 0.194 0.124 46.1 189 541 718 18 5.64 0.0692
IQR(TG43sim) 33.8 0.0872 0.189 0.191 48.1 213.3 129 1053 22.7 1.80 0.0331
MCref 82.05 0.858 0.439 0.185 24.3 31.8 2293 2293 44.39 7.86 0.151
TG43sim 88.95 0.894 0.542 0.274 15.6 21.6 1084 1228 60.38 1.65 0.068
%Δ -8.41 -4.2 -23.6 -47.8 36.0 32.2 52.72 46.44 36.02 79.03 55.3
MCref 85.8 0.883 0.665 0.383 116.5 152.8 319.5 1204 63.24 7.20 0.0894
TG43sim 96.6 0.924 0.742 0.525 91.1 121.5 55.43 1392 75.10 6.22 0.0687
%Δ -12.5 -4.6 -11.7 -37.3 21.8 20.5 82.7 -15.6 18.7 13.6 23.2
MCref 119.7 0.997 0.786 0.414 176.9 386.6 277.5 380.4 33.56 5.74 0.0671
TG43sim 144.7 1.000 0.944 0.631 160.0 376.5 41.50 268.1 47.82 1.48 0.0270
%Δ -20.9 -0.305 -20.0 -52.6 9.6 2.62 85.0 29.5 42.5 74.2 59.7
Abbreviations: %Δ = percent difference between MCref and TG43sim (see Eq. (1)); %Δavg = average percent difference over the 
cohort; %Δstd = standard deviation of percent differences; IQR = interquartile range of absolute doses (difference between third 
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